Highly selective inhibition of human CYP3Aa in vitro by azamulin and evidence that inhibition is irreversible.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Drug Metabolism And Disposition

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1124/DMD.32.1.105PMID 14709627
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Determination of CYP4A11-catalyzed lauric acid 12-hydroxylation by high-performance liquid chromatography with radiometric detection.

  2006cited by this paper
• Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts.

  2003influential reference
• The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective.

  2003cited by this paper
• Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors.

  2002cited by this paper
• Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4.

  2002cited by this paper
• Involvement of CYP2J2 on the intestinal first-pass metabolism of antihistamine drug, astemizole.

  2002influential reference
• Design and application of fluorometric assays for human cytochrome P450 inhibition.

  2002cited by this paper
• Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes.

  2002influential reference
• Inhibition of cytochromes P450 by antifungal imidazole derivatives.

  2002cited by this paper
• Optimizing Higher Throughput Methods to Assess Drug-Drug Interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 In Vitro Using a Single Point IC50

  2002cited by this paper
• Alternative splicing determines the function of CYP4F3 by switching substrate specificity.

  2001cited by this paper
• P450 interaction with farnesyl-protein transferase inhibitors metabolic stability, inhibitory potency, and P450 binding spectra in human liver microsomes.

  2001cited by this paper
• P450 interaction with HIV protease inhibitors: relationship between metabolic stability, inhibitory potency, and P450 binding spectra.

  2001cited by this paper
• P 450 Interaction with HIV Protease Inhibitors : Relationship between Metabolic Stability , Inhibitory Potency , and P 450 Binding Spectra

  2000cited by this paper
• Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates.

  2000cited by this paper
• Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450

  2000cited by this paper
• 13th International Symposium on Microsomes and Drug Oxidations

  2000cited by this paper
• Metabolic Drug Interactions

  2000cited by this paper
• Cytochrome P-450 1A1 expression in human small bowel: interindividual variation and inhibition by ketoconazole.

  1999cited by this paper
• Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P-450.

  1999cited by this paper
• CYP3A4 drug interactions: correlation of 10 in vitro probe substrates.

  1999cited by this paper
• Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potential.

  1999cited by this paper
• Determination of CYP4A11-catalyzed lauric acid 12-hydroxylation by high-performance liquid chromatography with radiometric detection.

  1998cited by this paper
• Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by alpha-naphthoflavone, terfenadine and testosterone.

  1998cited by this paper
• In vitro assessment of human cytochrome P450.

  1998cited by this paper
• Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450.

  1997cited by this paper
• Contemporary enzyme kinetics and mechanism

  1996cited by this paper
• Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes.

  1996cited by this paper
• Cytochrome P-450 complex formation in rat liver by the antibiotic tiamulin

  1996cited by this paper
• Tiamulin inhibits human CYP3A4 activity in an NIH/3T3 cell line stably expressing CYP3A4 cDNA.

  1995cited by this paper
• Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes.

  1995influential reference
• Mechanism-based enzyme inactivators.

  1995cited by this paper
• Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9.

  1995cited by this paper
• Evaluation of triacetyloleandomycin, alpha-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450.

  1994cited by this paper
• Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture

  1992cited by this paper
• Cytochrome P450 metabolic intermediate complexes from macrolide antibiotics and related compounds.

  1991influential reference
• Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene.

  1990cited by this paper
• A comparative study of 1-substituted imidazole and 1,2,4-triazole antifungal compounds as inhibitors of testosterone hydroxylations catalysed by mouse hepatic microsomal cytochromes P-450.

  1988cited by this paper
• Substrate interaction with cytochrome P-450.

  1981cited by this paper
• Antibiotic Substances From Basidiomycetes: VIII. Pleurotus Multilus (Fr.) Sacc. and Pleurotus Passeckerianus Pilat.

  1951cited by this paper

• Repression of bile salt efflux pump expression by tri-ortho-cresyl phosphate in cultured human hepatic cells.

  2025cites this paper
• Mitigating Antimicrobial Resistance through Strategic Design of Multimodal Antibacterial Agents Based on 1,2,3-Triazole with Click Chemistry

  2025cites this paper
• Linker and Head-Group Exploration of Anti-MRSA Triaromatic Pleuromutilins.

  2025cites this paper
• P24-26 In vitro metabolism of didecyldimethylammonium chloride in human hepatic cytochrome P450 enzymes

  2025cites this paper
• A Review on New Frontiers in Drug-Drug Interaction Predictions and Safety Evaluations with In Vitro Cellular Models

  2025cites this paper
• Antimicrobial Activity, Preliminary Safety, and Pharmacokinetics Assessment of 2-3: A Pleuromutilin-Derived Compound.

  2025cites this paper
• MD investigation on the differences in the dynamic interactions between the specific ligand azamulin and two CYP3A isoforms, 3A4 and 3A5

  2024cites this paper
• Enhancing Retinoic Acid-mediated Effects Through Inhibition of CYP26A1, CYP26B1 and HGF Signaling in Neuroblastoma Cells

  2024cites this paper
• Antimicrobial activity, safety and pharmacokinetics evaluation of PMTM: A novel pleuromutilin candidate.

  2024cites this paper
• Recent advances in developing modified C14 side chain pleuromutilins as novel antibacterial agents.

  2024cites this paper
• Hit-to-Lead Identification and Validation of a Triaromatic Pleuromutilin Antibiotic Candidate.

  2024cites this paper
• In vitro metabolic characterization of the SARS-CoV-2 papain-like protease inhibitors GRL0617 and HY-17542

  2023cites this paper
• Anti-methicillin-resistant Staphylococcus aureus activity and safety evaluation of 14-O-[(5-ethoxycarbonyl-4,6-dimethylpyrimidine-2-yl) thioacetyl] mutilin (EDT)

  2023cites this paper
• Rational utilization of 1,2,3-triazole scaffold in anti-MRSA drug development: Design strategies, Structural insights and Pharmacological outcomes

  2023cites this paper
• Synthesis and Biological Activities of Oxazolidinone Pleuromutilin Derivatives as a Potent Anti-MRSA Agent.

  2023cites this paper
• Research Progress of CYP450 Substrates, Inhibitors, Inducers and Species Specificity

  2023cites this paper
• Roles of human cytochrome P450 3A4/5 in dexamethasone 6β-hydroxylation mediated by liver microsomes and humanized liver in chimeric mice metabolically suppressed with azamulin.

  2023cites this paper
• Label-free chemical imaging of cytochrome P450 activity by Raman microscopy

  2022cites this paper
• Structural characterization of the homotropic cooperative binding of azamulin to human cytochrome P450 3A5

  2022influential citation
• Discovery of Novel Pleuromutilin Derivatives as Potent Antibacterial Agents for the Treatment of MRSA Infection

  2022cites this paper
• Synthesis, testing, and computational modeling of pleuromutilin 1,2,3-triazole derivatives in the ribosome

  2022cites this paper
• 1,2,3-Triazole-containing hybrids with potential antibacterial activity against ESKAPE pathogens.

  2022cites this paper
• Antibacterial activity evaluation of pleuromutilin derivatives with 4(3H)-quinazolinone scaffold against methicillin-resistant Staphylococcusaureus.

  2022cites this paper
• In Vitro and In Vivo Antibacterial Activity, Toxicity and Resistance Analysis of Pleuromutilin Derivative Z33 against Methicillin-Resistant Staphylococcus aureus

  2022influential citation
• Design, synthesis and biological evaluation of novel pleuromutilin derivatives as potent anti-MRSA agents targeting the 50S ribosome.

  2021cites this paper
• In vitro assessment of the potential for dolutegravir to affect hepatic clearance of levonorgestrel

  2021cites this paper
• Dietary Polyphenols Inhibit the Cytochrome P450 Monooxygenase Branch of the Arachidonic Acid Cascade with Remarkable Structure-Dependent Selectivity and Potency.

  2020cites this paper
• Cytochrome P450 inhibition potential and initial genotoxic evaluation of 14-O-[(4,6-diaminopyrimidine-2-yl)thioacetyl] mutilin

  2020cites this paper
• An integrated assessment of the ADME properties of the CDK4/6 Inhibitor ribociclib utilizing preclinical in vitro, in vivo, and human ADME data

  2020cites this paper
• Design, synthesis and biological activities of novel pleuromutilin derivatives with a substituted triazole moiety as potent antibacterial agents.

  2020cites this paper
• Application of Azamulin to Determine the Contribution of CYP3A4/5 to Drug Metabolic Clearance Using Human Hepatocytes

  2020influential citation
• iTAG-RNA Isolates Cell-Specific Transcriptional Responses to Environmental Stimuli and Identifies an RNA-Based Endocrine Axis.

  2020cites this paper
• Synthesis, biological activities and docking study of novel chalcone-pleuromutilin derivatives.

  2020cites this paper
• Switching a Xanthine Oxidase Inhibitor to a Dual-Target Antagonist of P2Y1 and P2Y12 as an Oral Antiplatelet Agent with a Wider Therapeutic Window in Rats than Ticagrelor.

  2020cites this paper
• Using in vitro methods to determine P450s responsible for metabolism and discrimination from other oxidative pathways

  2020cites this paper
• Design, synthesis and biological evaluation of novel pleuromutilin derivatives containing piperazine and 1,2,3-triazole linker.

  2020cites this paper
• Inhibition and induction of CYP enzymes in humans: an update

  2020cites this paper
• Strong and Selective Inhibitory Effects of the Biflavonoid Selamariscina A against CYP2C8 and CYP2C9 Enzyme Activities in Human Liver Microsomes

  2020cites this paper
• Different roles of human cytochrome P450 2C9 and 3A enzymes in diclofenac 4'- and 5-hydroxylations mediated by metabolically inactivated human hepatocytes in previously transplanted chimeric mice.

  2019cites this paper
• Structural Insights into the Interaction of Cytochrome P450 3A4 with Suicide Substrates: Mibefradil, Azamulin and 6′,7′-Dihydroxybergamottin

  2019cites this paper
• Antibacterial properties and clinical potential of pleuromutilins.

  2019cites this paper
• Neonatal cytochrome P450 CYP3A7: A comprehensive review of its role in development, disease, and xenobiotic metabolism.

  2019cites this paper
• In-vivo targeted tagging of RNA isolates cell specific transcriptional responses to environmental stimuli and identifies liver-to-adipose RNA transfer

  2019cites this paper
• In vitro phase I metabolism of vinclozolin by human liver microsomes

  2019influential citation
• Screening of ten cytochrome P450 enzyme activities with 12 probe substrates in human liver microsomes using cocktail incubation and liquid chromatography–tandem mass spectrometry

  2019cites this paper
• CYP2J2 is the major enzyme in human liver microsomes responsible for hydroxylation of SYL‐927, a novel and selective sphingosine 1‐phosphate receptor 1 (S1P1) agonist

  2018influential citation
• Adverse Neuropsychiatric Events and Recreational Use of Efavirenz and Other HIV-1 Antiretroviral Drugs

  2018cites this paper
• Glaucarubulone glucoside from Castela macrophylla suppresses MCF‐7 breast cancer cell growth and attenuates benzo[a]pyrene‐mediated CYP1A gene induction

  2017influential citation
• Synthesis and Biological Evaluation of Novel Thioether Pleuromutilin Derivatives.

  2017cites this paper
• Design, synthesis and antibacterial evaluation of novel pleuromutilin derivatives possessing piperazine linker.

  2017cites this paper
• Direct and quantitative evaluation of the human CYP3A4 contribution (fm) to drug clearance using the in vitro SILENSOMES model

  2017influential citation
• Hydroxylation of 20-hydroxyvitamin D3 by human CYP3A4.

  2016cites this paper
• Food Polyphenol Apigenin Inhibits the Cytochrome P450 Monoxygenase Branch of the Arachidonic Acid Cascade.

  2016cites this paper
• Mechanism-based inactivation of human cytochrome P450 1A2 and 3A4 isoenzymes by anti-tumor triazoloacridinone C-1305

  2016influential citation
• Complexity of vitamin E metabolism.

  2016cites this paper
• Design and Synthesis of Molecular Scaffolds with Anti-infective Activity.

  2016cites this paper
• Improvement of the chemical inhibition phenotyping assay by cross-reactivity correction

  2016cites this paper
• Synthesis and Pharmacological Evaluation of Novel Pleuromutilin Derivatives with Substituted Benzimidazole Moieties

  2016cites this paper
• Hierarchical mechanistic modelling of clinical pharmacokinetic data

  2016cites this paper
• Phenotypic and metabolic investigation of a CSF-1R kinase receptor inhibitor (BLZ945) and its pharmacologically active metabolite

  2015cites this paper
• Application of a Bayesian approach to physiological modelling of mavoglurant population pharmacokinetics

  2015cites this paper
• Inhibition of in vitro metabolism of testosterone in human, dog and horse liver microsomes to investigate species differences.

  2015cites this paper
• Reaction Phenotyping: Advances in the Experimental Strategies Used to Characterize the Contribution of Drug-Metabolizing Enzymes

  2015cites this paper
• Investigating the chemical space and metabolic bioactivation of natural products and cross-reactivity of chemical inhibitors in CYP450 phenotyping

  2014cites this paper
• CYP-dependent metabolism of antitumor pyrazolo[3,4-d]pyrimidine derivatives is characterized by an oxidative dechlorination reaction.

  2014cites this paper
• CYP3A4 activity reduces the cytotoxic effects of okadaic acid in HepaRG cells

  2014cites this paper
• The Metabolic Drug-Drug Interaction Profile of Dabrafenib: In Vitro Investigations and Quantitative Extrapolation of the P450-Mediated DDI Risk

  2014cites this paper
• Design, synthesis, and structure-activity relationship studies of novel thioether pleuromutilin derivatives as potent antibacterial agents.

  2014cites this paper
• The effect of the Pheroid delivery system on the in vitro metabolism and in vivo pharmacokinetics of artemisone

  2014cites this paper
• The Revised Human Liver Cytochrome P450 “Pie”: Absolute Protein Quantification of CYP4F and CYP3A Enzymes Using Targeted Quantitative Proteomics

  2014cites this paper
• In Vitro CYP/FMO Reaction Phenotyping

  2014cites this paper
• The metabolic drug-drug interaction profile of dabrafenib: In vitro investigations and quantitative extrapolation of the P450-mediated DDI risk

  2014cites this paper
• Microsoft Word-90329935-file00.docx

  2014cites this paper
• DMD058040 1241..1251

  2014cites this paper
• The metabolic drug-drug interaction profile of dabrafenib: In vitro investigations and quantitative extrapolation of the P450-mediated DDI risk

  2014cites this paper
• Cytochrome P450 2J2: distribution, function, regulation, genetic polymorphisms and clinical significance

  2013influential citation
• Predicting the Drug Interaction Potential of AMG 853, a Dual Antagonist of the D-Prostanoid and Chemoattractant Receptor-Homologous Molecule Expressed on T Helper 2 Cells Receptors

  2012cites this paper
• Imidazopyridines as selective CYP3A4 inhibitors.

  2012cites this paper
• Hypertonicity Regulation of Cytochrome P450 CYP3A

  2012cites this paper
• 13. Reaction Phenotyping

  2012cites this paper
• In vitro characterization of the oxidation of a pyridinium metabolite of haloperidol by human placenta: the effect of smoking.

  2012influential citation
• A clinical study to assess CYP1A2 and CYP3A4 induction by AZD7325, a selective GABA(A) receptor modulator - an in vitro and in vivo comparison.

  2012cites this paper
• Ilaprazole, a new proton pump inhibitor, is primarily metabolized to ilaprazole sulfone by CYP3A4 and 3A5

  2012cites this paper
• Discovery of a Highly Selective CYP3A4 Inhibitor Suitable for Reaction Phenotyping Studies and Differentiation of CYP3A4 and CYP3A5

  2012cites this paper
• Assessment of the Drug Interaction Risk for Remogliflozin Etabonate, a Sodium-Dependent Glucose Cotransporter-2 Inhibitor: Evidence from In Vitro, Human Mass Balance, and Ketoconazole Interaction Studies

  2012influential citation
• Mitochondria are the primary source of the H(2)O(2) signal for glucocorticoid-induced apoptosis of lymphoma cells.

  2012cites this paper
• Cytotoxic and potent CYP1 inhibitors from the marine algae Cymopolia barbata

  2012cites this paper
• Predicting the Drug Interaction Potential of AMG 853, a Dual Antagonist of the D-Prostanoid (DP) and Chemoattractant Receptor-Homologous Molecule Expressed on TH2 Cells (CRTH2) Receptors

  2012cites this paper
• Microsoft Word-24354746-file00.docx

  2012cites this paper
• Assessment of the Drug Interaction Risk for Remogliflozin Etabonate, a Sodium-Dependent Glucose Co-Transporter-2 Inhibitor: Evidence from In Vitro, Human Mass Balance and Ketoconazole Interaction Studies.

  2012cites this paper
• Genotoxicity and potential carcinogenicity of cyanobacterial toxins - a review.

  2011cites this paper
• Oxidative mechanisms for the biotransformation of 1-methyl-1,6-dihydropyridine-2-carbaldoxime to pralidoxime chloride.

  2011cites this paper
• Flavin monooxygenases, FMO1 and FMO3, not cytochrome P450 isoenzymes, contribute to metabolism of anti-tumour triazoloacridinone, C-1305, in liver microsomes and HepG2 cells

  2011cites this paper
• Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity

  2011cites this paper
• In Vitro Evaluation of Potential Drug-Drug Interactions with Ticagrelor: Cytochrome P450 Reaction Phenotyping, Inhibition, Induction, and Differential Kinetics

  2011cites this paper
• Comparative study of culture conditions for maintaining CYP3A4 and ATP-binding cassette transporters activity in primary cultured human hepatocytes.

  2011cites this paper
• Cytochrome P450 1 enzyme inhibition and anticancer potential of chromene amides from Amyris plumieri.

  2011cites this paper
• Whole-cell biotransformation assay for investigation of the human drug metabolizing enzyme CYP3A7.

  2011cites this paper
• CYP4F Enzymes Are Responsible for the Elimination of Fingolimod (FTY720), a Novel Treatment of Relapsing Multiple Sclerosis

  2011influential citation
• Potential of hydroxyebastine and terfenadine alcohol to inhibit the human cytochrome P450 2J2 isoform

  2011cites this paper